Not Yet RecruitingNot Applicable

Impact of Sacubitril/Valsartan on LV Diastolic Function in HFrEF

70 participantsStarted 2026-06-01

Plain-language summary

This prospective cohort study evaluates the effects of six months of sacubitril/valsartan (ARNI) therapy on left ventricular diastolic function in patients with heart failure with reduced ejection fraction (HFrEF) using transthoracic echocardiography. It aims to correlate echocardiographic parameters with clinical status and systolic function among Egyptian patients treated at two cardiology centers.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with HFrEF (LVEF \< 35%) * Able to tolerate and comply with ARNI therapy * Patients on Guideline-Directed Medical Therapy (GDMT) for heart failure Exclusion Criteria: * Patients with contraindication to ARNI therapy * Patients with poor echocardiographic window * Patients non-compliant with medication or follow-up * Patients with mitral significant lesion or mitral prosthesis. * Patients with atrial arrhythmia or on pacemaker

What they're measuring

Change in Left Ventricular Diastolic Function

Timeframe: Baseline

Trial details

NCT IDNCT07157527

SponsorAssiut University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-09-30

View on ClinicalTrials.gov More Left Ventricular Diastolic Function trials